

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **UCNTTF** Tumour-Treating Fields for Glioblastoma
- **GOCXPEMCR**T Pembrolizumab and Chemoradiation for Locally Advanced Cervical Cancer
- **GOEAVPCAT, GOEAVPPNC** Pembrolizumab, Chemotherapy for Advanced or Recurrent Endometrial Cancer
- **GUOTTIP** Neoadjuvant Paclitaxel, Ifosfamide and Cisplatin for Penile Carcinoma
- **ULKAMLAZIV** Azacitidine and Ivosidenib for AML
- **LULAOSI** Osimertinib for Locally Advanced *EGFR*+ NSCLC
- **LUMMPPPMB** Platinum, Pemetrexed and Pembrolizumab for Malignant Mesothelioma
- **LYLENR** Lenalidomide, Rituximab in Non-Hodgkin Lymphoma

Practice Standards and Policies

Dose Banding avelumab, enfortumab vedotin, sacituzumab govitecan, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine

Provincial Systemic Therapy Policy Documents

Transition from Reference Biologics to Biosimilars: Denosumab

Cancer Drug Manual®

Revised eribulin, ivosidenib

Chemotherapy Preparation and Stability Chart aldesleukin, belantamab mafodotin, cyclophosphamide, eribulin, ifosfamide, mirvetuximab soravtansine

Oncology High-Alert Medications belantamab mafodotin, inavolisib

Continuing Education

Family Practice Oncology Network

- **Webinar** Sexual Health in Cancer Care
- **Annual Education Day** Cancer Treatment-Related Toxicities

Community Oncology Network

OSCAR Billing Deadline

Benefit Drug List

New GOCXPEMCR, GOEAVPCAT, GOEAVPPNC, GUOTTIP, ULKAMLAZIV, LULAOSI, LUMMPPPMB, LYLENR

Revised GOEAVDCAT, GOEAVDPNC, LUNANIVPC, LUNANIVPP

Protocols, PPPOs and Patient Handouts

New **CN** UCNTTF **GO** GOCXPEMCR, GOEAVPCAT, GOEAVPPNC **GU** GUOTTIP **LK** ULKAMLAZIV **LU** LULAOSI, LUMMPPPMB **LY** LYLENR

Revised **BR** BRAJACTT, BRAJACTTG, BRAJDCARBT, BRAJFECDT, UBRAJKAD, BRAJPNCT, BRAJPNT, BRAJTDC, BRAJTR, BRAJTTW, BRAVENH, BRAVKAD, BRAVPTRAD, BRAVPTRAT, BRAVPTRVIN, BRAVSG, BRAVTCAP, BRAVTR, UBRAVTTCAP, BRLAACDT **GI** GIGAVCCT, GIGAVCFT, GIGAVCOXT, GIGAVENH, GIGAVFFOXT, GIGAVPCOXT, GIGAVPFOXT, GIGAVTR **GO** UGOCXCATBP, UGOCXCATP, GOEAVDCAT, GOEAVDPNC **GU** GUAVEV, GUAVEVPEM, GUBAVE, GUSUNI **LU** LUMMIPNI, LUMMIPNI3, LUNANIVPC, LUNANIVPP **LY** LYAVDNIV, LYPOLARCHP **SM** SMMCCAVE

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 March 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Neuro-Oncology

Tumour-Treating Fields (OPTUNE GIO®) for Glioblastoma (UCNTTF) – The BC Cancer Neuro-Oncology Tumour Group is introducing tumour-treating fields (TTF) as treatment for patients with newly diagnosed glioblastoma (GBM). OPTUNE GIO® is a portable medical device producing alternating electrical fields, or

Editor's Choice

TTF, to target growth of cancerous cells.^{1,2} Following maximal debulking surgery and chemoradiotherapy with temozolomide, TTF must be used at least 18 hours per day, starting during the adjuvant temozolomide phase of treatment. Localized skin toxicity is the most frequently reported adverse effect with this treatment; reactions may include skin irritation, contact dermatitis, hyperhidrosis, pruritus, skin erosions and infections. Note that the protocol and patient handout were made available on the BC Cancer website as of 01 February 2026. BC Cancer Compassionate Access Program (CAP) approval is required. All referrals and healthcare provider inquiries should be forwarded to ProvincialTxCoordination@bccancer.bc.ca.

The open-label, randomized controlled EF-14 trial investigated the use of TTF with and after adjuvant temozolomide, compared with adjuvant temozolomide alone.^{1,2} The use of TTF improved progression-free survival (PFS) and overall survival (OS), representing the first new treatment option to improve survival in GBM since 2005. The incidence of localized skin toxicity was higher in patients treated with TTF.

Gynecologic Oncology

Pembrolizumab, Cisplatin and Radiation Therapy for Locally Advanced Cervical Cancer (GOCXPEMCR) – The BC Cancer Gynecologic Oncology Tumour Group is implementing pembrolizumab in combination with cisplatin chemoradiotherapy for the treatment of newly diagnosed, stage III-IVA locally advanced cervical cancer (LACC). Pembrolizumab and cisplatin are given concurrently with radiation therapy; pembrolizumab is continued as monotherapy after radiation therapy is completed.

The randomised, placebo-controlled, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial demonstrated that pembrolizumab in combination with chemoradiotherapy and then continued after chemoradiotherapy resulted in PFS and OS benefit compared with chemoradiotherapy alone in patients with previously untreated LACC.^{3,4,5} The safety profiles were consistent with the known profiles of each regimen.

Treatment for Advanced or Recurrent Endometrial Cancer:

Pembrolizumab, Carboplatin and Paclitaxel	(GOEAVPCAT)
Pembrolizumab, Carboplatin and Paclitaxel NAB as Alternative Treatment	(GOEAVPPNC)

The BC Cancer Gynecologic Oncology Tumour Group is also implementing pembrolizumab with carboplatin-paclitaxel, then as pembrolizumab monotherapy, for newly diagnosed stage III or IVA endometrial cancer with measurable disease or stage IVB or recurrent endometrial cancer. Alternative treatment with paclitaxel NAB is available for patients with previous moderate or severe hypersensitivity reaction to paclitaxel that is not manageable with premedications.

The randomized phase III NRG-GY018 trial demonstrated that pembrolizumab plus carboplatin-paclitaxel followed by pembrolizumab monotherapy, compared with treatment without pembrolizumab, in patients with primary advanced or recurrent endometrial cancer, resulted in improved PFS.^{6,7,8} Adverse events were as expected for pembrolizumab and combination chemotherapy.

Genitourinary

Neoadjuvant Paclitaxel, Ifosfamide and Cisplatin for Penile Carcinoma (GUOTTIP) – The BC Cancer Genitourinary Tumour Group is implementing modified TIP (paclitaxel, ifosfamide and cisplatin) for the neoadjuvant treatment of patients with penile squamous cell carcinoma prior to planned surgical resection. Treatment is delivered in an inpatient setting with mesna and hydration support. This treatment program

Editor's Choice

is supported by a phase II study that established the efficacy of TIP in the neoadjuvant setting for patients with bulky regional lymph node metastases from penile cancer.⁹

Leukemia/BMT

Azacitidine and Ivosidenib for Acute Myeloid Leukemia (ULKAMLAZIV) – The BC Cancer Leukemia and BMT Tumour Group is introducing combination treatment with azacitidine and ivosidenib for newly diagnosed *IDH1*-mutated acute myeloid leukemia (AML) in patients who are ineligible for standard intensive induction chemotherapy. Ivosidenib, an oral small molecule inhibitor, targets mutant isocitrate dehydrogenase 1 (*IDH1*) enzyme. Monitoring and management for differentiation syndrome and QT prolongation from ivosidenib are outlined in the treatment protocol. At the time of dispensing, pharmacy will provide patients with an ivosidenib patient alert card for differentiation syndrome. BC Cancer CAP approval is required.

The placebo-controlled, phase III AGILE trial demonstrated that ivosidenib in combination with azacitidine resulted in improvements in event-free survival (EFS) and OS in patients with newly diagnosed AML with an *IDH1 R132* mutation who were not eligible to receive intensive induction chemotherapy.^{10,11,12} Adverse events of special interest occurred more frequently in the ivosidenib-azacitidine group, including QT prolongation, differentiation syndrome and leukocytosis.

Lung

Osimertinib for Locally Advanced *EGFR*+ Non-Small Cell Lung Cancer (LULAOSI) – The BC Cancer Lung Tumour Group is implementing osimertinib for the treatment of locally advanced, unresectable stage III epidermal growth factor receptor (*EGFR*) mutation-positive non-small cell lung cancer (NSCLC), in patients whose disease has not progressed during or after platinum-based chemoradiation therapy.

The placebo-controlled phase III LAURA trial demonstrated that osimertinib maintenance therapy resulted in a clinical benefit in patients with locally advanced, unresectable stage III *EGFR*+ NSCLC whose disease has not progressed during or following platinum-based chemoradiation.^{13,14} The trial demonstrated that, compared with placebo, osimertinib resulted in improved objective response rate, duration of response and PFS. The safety profile of osimertinib appeared consistent with its known adverse effects.

Pembrolizumab, Platinum and Pemetrexed for Malignant Mesothelioma (LUMMPMPMB) – The BC Cancer Lung Tumour Group is implementing pembrolizumab with platinum and pemetrexed for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The initial induction component includes pembrolizumab, platinum and pemetrexed for 6 cycles, followed by pembrolizumab maintenance.

The randomized, controlled phase II/III KEYNOTE-483 trial demonstrated improved OS with pembrolizumab in combination with chemotherapy in patients with MPM compared with chemotherapy alone.^{15,16} Despite a higher incidence of adverse events with the addition of pembrolizumab, there was no detrimental effect on patient-reported quality of life.

Lymphoma

Lenalidomide and Rituximab for Treatment of Non-Hodgkin Lymphoma (LYLENR) – The BC Cancer Lymphoma Tumour Group is implementing lenalidomide and rituximab for the treatment of relapsed or refractory grades 1 to 3a follicular lymphoma or marginal zone lymphoma with at least one prior line of

Editor's Choice

treatment. Registration of the prescribing physician and patient with the RevAid Program (www.RevAid.ca) is required.

The randomized phase III AUGMENT trial was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma.^{17,18,19} Progression-free survival was improved for patients randomized to lenalidomide plus rituximab versus placebo plus rituximab. Infections, neutropenia and cutaneous reactions were more common with lenalidomide plus rituximab.

References:

1. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Optune® (NovoTTF-200A). *Canadian Journal of Health Technologies* 2024;4(3):1-18. <https://doi.org/10.51731/cjht.2024.859>
2. Stupp R, Taillibert S, Kanneret A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA* 2017;318(23):2306-2316. <https://doi.org/10.1001/jama.2017.18718>
3. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2025;5(10):1-24. <https://doi.org/10.51731/cjht.2025.1259>
4. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. *Lancet* 2024;403(10434):1341-1350. [https://doi.org/10.1016/S0140-6736\(24\)00317-9](https://doi.org/10.1016/S0140-6736(24)00317-9)
5. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2024;404(10460):1321-1332. [https://doi.org/10.1016/S0140-6736\(24\)01808-7](https://doi.org/10.1016/S0140-6736(24)01808-7)
6. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2025;5(6):1-24. <https://doi.org/10.51731/cjht.2025.1149>
7. Eskander RN, Sill MW, Beffa L et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med* 2023; 388:2159-2170. <https://doi.org/10.1056/NEJMoa2302312>
8. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. *Nature Medicine* 2025;31:1539-1546. <https://doi.org/10.1038/s41591-025-03566-1>
9. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. *J Clin Oncol* 2010;28(24):3851-3857. <https://doi.org/10.1200/JCO.2010.29.5477>
10. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Ivosidenib (Tibsovo®). *Canadian Journal of Health Technologies* 2024;4(10):1-32. <https://doi.org/10.51731/cjht.2024.1008>
11. Montesinos P, Récher C, Vives S, et al. Ivosidenib and azacitidine in *IDH1*-mutated acute myeloid leukemia. *N Engl J Med* 2022;386(16):1519-1531. <https://doi.org/10.1056/NEJMoa2117344>
12. Montesinos P, Marchione DM, Récher C, et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed *IDH1*-mutated AML. *Blood Adv* 2025;9(20):5177-5189. <https://doi.org/10.1182/bloodadvances.2025016399>
13. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Osimertinib (Tagrisso®). *Canadian Journal of Health Technologies* 2025;5(9):1-28. <https://doi.org/10.51731/cjht.2025.1224>
14. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. *N Engl J Med* 2024;391(7): 585-597. <https://doi.org/10.1056/NEJMoa2402614>
15. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2025;5(7):1-25. <https://doi.org/10.51731/cjht.2025.1172>
16. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. *Lancet* 2023;402(10419):2295-2306. [https://doi.org/10.1016/S0140-6736\(23\)01613-6](https://doi.org/10.1016/S0140-6736(23)01613-6)
17. CADTH. Health Technology Rapid Review. Lenalidomide plus rituximab chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphomas. *Canadian Journal of Health Technologies* 2021;1(11):1-58. <https://doi.org/10.51731/cjht.2021.203>
18. Leonard J, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. *J Clin Oncol* 2019;37(14):1188-1199. <https://doi.org/10.1200/JCO.19.00010>
19. Leonard J, Trneny M, Offner F, et al. Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. *Blood* 2022;140(Supplement 1):561-563. <https://doi.org/10.1182/blood-2022-158631>

Practice Standards and Policies

All Systemic Therapy policies and procedures are on the BC Cancer page of [Shared Health Organizations Portal \(SHOP\)](#).

Dose Banding: Avelumab, Enfortumab Vedotin, Sacituzumab Govitecan, Trastuzumab

As part of the continued dose banding rollout at BC Cancer:

- standardized dose bands for **avelumab, enfortumab vedotin, sacituzumab govitecan, trastuzumab, trastuzumab deruxtecan** and **trastuzumab emtansine** have been integrated into all protocols, provincial preprinted orders (PPPOs) and the Cerner system as of 01 March 2026
- dose banding will continue in April 2026 with brentuximab vedotin and rituximab
- Systemic Therapy [Procedure III-140: Management of Dose Banded Cancer Drug Treatments](#) continues to be updated to reflect the drugs approved for dose banding
- [Dose Banding Tables](#) are posted in the Cancer Drug Manual[®] Appendix

Provincial Systemic Therapy Policy Documents

Provincial Systemic Therapy has updated policy document **III-120 Guidelines for Scheduling Patients for Parenteral Systemic Therapy**. The guidelines will go live on SHOP the week of March 09, with internal communications and education starting prior.

Updates include:

- Converted from policy to guideline as more appropriate for content (formerly titled Policy III-120 Scheduling IV Systemic Therapy Patients)
- "Other treatments" section added for radiopharmaceuticals (i.e., PLUVICTO[®])
- Updated booking adjustments table for adjuvant treatment
- Guidance for pharmacy and clerks when appointments rescheduled due to stat holiday or capacity:
 - *Repeat labs only required if ordered by provider*
 - *Repeat labs not recommended when:*
 - Capacity is the only reason for treatment delay
 - Rescheduled appointment within 1 week of original scheduled appointment
 - Labs drawn within appropriate time frame of original appointment
 - Lab results within acceptable range for protocol
- Documentation guidance for clerks and pharmacy around repeat labs
- If patient delayed by more than 1 week and up to 2 weeks due to capacity, pharmacist will order repeat labs without provider's order

Transition from Reference Biologics to Biosimilars: Denosumab

Long-term clinical evidence supports the comparability between the reference biologic denosumab (XGEVA) with its biosimilar (WYOST). As such, BC Cancer will be transitioning all remaining patients being treated with this reference biologic to its biosimilar on or after 01 April 2026.

Providers with patients on XGEVA are encouraged to speak with their patients about this transition ahead of 01 April 2026. This will prevent any treatment delays if patients have questions about the transition.

Practice Standards and Policies

Staff can leverage the patient fact sheet if patients have questions about their transition. The patient fact sheet, [Transitioning to a Biosimilar Drug](#), is found in the Biosimilar Drugs section of the BC Cancer website.

After 01 April 2026, access to XGEVA will require BC Cancer Compassionate Access Program (CAP) approval. Approval will only be granted for safety or significant adverse event reasons.

There will be no changes to the Cerner PowerPlan or PPPO for BC Cancer treatment protocol SANADENO.

Questions can be sent to ProvincialSystemicOffice@bccancer.bc.ca.

Cancer Drug Manual[©]

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

Revised Documents

Eribulin Monograph and Chemotherapy Preparation and Stability Chart

Supply and Storage: added new brand (Dr Reddy's)

Ivosidenib Monograph and Patient Handout

Header/Footer: removed "interim" designation

Dosage Guidelines: added new BC Cancer protocol ULKAMLAZIV; bolded and italicized BC Cancer standard dosing

Patient Handout: removed "interim" designation from Header/Footer

Chemotherapy Preparation and Stability Chart

Aldesleukin: updated manufacturer for SteriMax brand to Iovance/Bioscript; deleted Iovance USA brand (which was temporarily imported for drug shortage)

Belantamab mafodotin: added new brand (Glaxo); deleted both SAP brands (GSK)

Cyclophosphamide: updated final product stability to include extended stability information for SteriMax and Baxter brands

Eribulin: added new brand (Dr Reddy's)

Ifosfamide: added new brand (Baxter USA) temporarily imported for drug shortage; deleted Fresenius Kabi brand as no longer marketed in Canada per Health Canada

Mirvetuximab soravtansine: added new brand (AbbVie); deleted SAP supply (AbbVie EU)

Oncology High-Alert Medications List

Belantamab mafodotin and **inavolisib** have been added to the [Oncology High-Alert Medications List](#).

Continuing Education

Family Practice Oncology Network | Webinar

The Family Practice Oncology Network (FPON) is pleased to announce a webinar on **Sexual Health in Cancer Care** with Dr. Shauna Correia. The webinar is Thursday 19 March 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Describe the potential impact of cancer and cancer treatment on sexual health
- Discuss initial management of sexual health impacted by cancer and cancer treatment
- Cite point of care resources

For more information and link to registration, visit:

[FPON Webinar | Sexual Health in Cancer Care | UBC CPD](#)

Family Practice Oncology Network | Annual Education Day

The FPON's accredited **Annual Education Day** entitled **Cancer Treatment-Related Toxicities: Practical Pearls for Primary Care Providers** takes place Saturday 11 April 2026, from 0800-1315h.

When patients with cancer present to the office with symptoms, primary care providers play a key role in identifying treatment-related toxicities. With more therapy options than ever before, join FPON for this year's Annual Education Day, designed to help primary care providers recognize treatment-related toxicities and consider next steps in the primary care office setting while connecting with their oncology colleagues. Each interactive session will include 30 minutes of practical knowledge followed by 15 minutes of Q&A.

By the end of the sessions, participants will be able to:

- Differentiate between major types of cancer therapies
- Promptly recognize some common and clinically significant toxicities associated with each type of cancer therapy
- Apply practical strategies to assess and initiate early management steps of these toxicities in the primary care office setting
- Identify and initiate management of cancer associated thromboses

For the agenda and registration (\$89) link, visit: [FPON Annual Education Day | Cancer Treatment-Related Toxicities: Practical Pearls for Primary Care Providers | UBC CPD](#)

Community Oncology Network (CON)

2025-2026 OSCAR Billing Deadline: 02 April 2026 @ Noon

The 2025-2026 fiscal year will end on **Tuesday 31 March 2026**. To meet the deadline for external reporting to the Ministry of Health, all claims for drug reimbursement for the current fiscal year must be submitted by **noon on Thursday 02 April 2026** via OSCAR (Online System for Cancer Drugs Adjudication and Reimbursement). Any claims submitted after this date will not be eligible for reimbursement. For more information, please email oscar@bccancer.bc.ca.

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 March 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Locally Advanced Cervical Cancer with Pembrolizumab, Cisplatin and Radiation Therapy	GOCXPEMCRT	Class I
Treatment of Advanced or Recurrent Endometrial Cancer using Carboplatin, Paclitaxel, and Pembrolizumab	GOEAVPCAT	Class I
Alternative Treatment of Advanced or Recurrent Endometrial Cancer using Pembrolizumab, Paclitaxel NAB and Carboplatin	GOEAVPPNC	Class I
Neoadjuvant Therapy for Penile Squamous Cell Carcinoma using Paclitaxel, Ifosfamide and Cisplatin (TIP)	GUOTTIP	Class I
Therapy of Acute Myeloid Leukemia using Azacitidine and Ivosidenib	ULKAMLAZIV	Restricted
Treatment of Locally Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib	LULAOSI	Class I
Treatment of Malignant Mesothelioma using Platinum, Pemetrexed and Pembrolizumab	LUMMPPMB	Class I
Treatment of Non-Hodgkin Lymphoma with Lenalidomide and Rituximab	LYLENR	Class I

Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 March 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel ✓ Requirement for CAP approval removed: UGOEAVDCAT → GOEAVDCAT	GOEAVDCAT	Class I
Alternative Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin ✓ Requirement for CAP approval removed: UGOEAVDPNC → GOEAVDPNC	GOEAVDPNC	Class I
Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, Carboplatin and Paclitaxel ✓ Protocol code revised to reflect neoadjuvant use: LUNANIVPC → LUNANIVPC	LUNANIVPC	Class I
Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum ✓ Protocol code revised to reflect neoadjuvant use: LUNANIVPP → LUNANIVPP	LUNANIVPP	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOXPMECMT	Treatment of Locally Advanced Cervical Cancer with Pembrolizumab, Cisplatin and Radiation Therapy	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GOEAVPCAT	Treatment of Advanced or Recurrent Endometrial Cancer using Carboplatin, Paclitaxel and Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GOEAVPPNC	Alternative Treatment of Advanced or Recurrent Endometrial Cancer using Pembrolizumab, Paclitaxel NAB and Carboplatin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GUOTTIP	Neoadjuvant Therapy for Penile Squamous Cell Carcinoma using Paclitaxel, Ifosfamide and Cisplatin (TIP)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Inpatient	<input checked="" type="checkbox"/>
ULKAMLAZIV	Therapy of Acute Myeloid Leukemia using Azacitidine and Ivosidenib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LULAOSI	Treatment of Locally Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LUMMPPMB	Treatment of Malignant Mesothelioma using Platinum, Pemetrexed and Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 2 x PPPOs	<input type="checkbox"/>
LYLENR	Treatment of Non-Hodgkin Lymphoma with Lenalidomide and Rituximab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 3 x PPPOs	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJACTT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab	<i>Dose banding added; contact information, exclusions and units of measure clarified</i>	<i>Dose banding added; units of measure clarified</i>	---
BRAJACTTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab	<i>Dose banding added; contact information updated; eligibility, exclusions and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJDCARBT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin and Trastuzumab	<i>Dose banding added; contact information, exclusions and units of measure clarified</i>	<i>Dose banding added; units of measure clarified</i>	---
BRAJFECDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Dose banding added; contact information and exclusions updated; units of measure clarified</i>	<i>Dose banding added; units of measure clarified</i>	---
UBRAJKAD	Adjuvant Therapy for Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<i>Dose banding added; contact information updated; exclusions, tests and units of measure clarified</i>	<i>Dose banding added; height/BSA removed; tests, treatment and units of measure clarified</i>	---
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB, Carboplatin and Trastuzumab	<i>Dose banding added</i>	<i>Dose banding added</i>	---
BRAJPNT	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	<i>Dose banding added; exclusions clarified</i>	<i>Dose banding added</i>	---
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Trastuzumab, Docetaxel and Cyclophosphamide	<i>Dose banding added; eligibility, exclusions and units of measure clarified</i>	<i>Dose banding added; units of measure and premedications clarified</i>	---
BRAJTR	Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion of Chemotherapy (Sequential)	<i>Dose banding added; contact information updated; eligibility, exclusions, tests and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
BRAJTTW	Adjuvant Therapy for Breast Cancer using Weekly Paclitaxel and Trastuzumab	<i>Dose banding added; contact information updated; eligibility, exclusions, units of measure and tests clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
BRAVENH	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	<i>Dose banding added; contact info updated; tests and units of measure clarified</i>	<i>Dose banding added; height/BSA removed; treatment, tests and units of measure clarified</i>	---
BRAVKAD	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<i>Dose banding added; contact information updated; tests and units of measure clarified</i>	<i>Dose banding added; height/BSA removed; treatment, tests and units of measure clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAVPTRAD	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer	<i>Dose banding added; tests and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
BRAVPTRAT	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	<i>Dose banding added; contact information updated; tests and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
BRAVPTRVIN	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	<i>Dose banding added</i>	<i>Dose banding added</i>	---
BRAVSG	Palliative Therapy for Metastatic Breast Cancer using Sacituzumab Govitecan	<i>Dose banding added; contact physician updated</i>	<i>Dose banding added</i>	---
BRAVTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine	<i>Dose banding added; eligibility clarified</i>	<i>Dose banding added; tests clarified</i>	---
BRAVTR	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab	<i>Dose banding added; contact information updated; eligibility, tests and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
UBRAVTTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	<i>Dose banding added; contact information updated</i>	<i>Dose banding added; tests clarified</i>	---
BRLAACDT	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Dose banding added; contact information updated; eligibility, exclusions and units of measure clarified</i>	<i>Dose banding added; units of measure clarified</i>	---
GI Gastrointestinal				
GIGAVCCT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	<i>Dose banding added; contact information clarified</i>	<i>Dose banding added</i>	---
GIGAVCFT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Cisplatin, Infusional Fluorouracil and Trastuzumab	<i>Dose banding added; contact information updated; units of measure clarified</i>	<i>Dose banding added; units of measure clarified</i>	---
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab	<i>Dose banding added; contact information and units of measure updated</i>	<i>Dose banding added</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIGAVENH	Second-Line Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Trastuzumab Deruxtecan (ENHERTU)	<i>Dose banding added; tests, units of measure clarified</i>	<i>Dose banding added; height/BSA removed; units of measure clarified</i>	---
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Dose banding added; units of measure clarified; contact information updated</i>	<i>Dose banding added; treatment and units of measure clarified</i>	---
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	<i>Dose banding added</i>	<i>Dose banding added</i>	---
GIGAVPFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Dose banding added</i>	<i>Dose banding added</i>	---
GIGAVTR	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Trastuzumab	<i>Dose banding added; contact information updated; tests clarified</i>	<i>Dose banding added</i>	---
GO Gynecologic Oncology				
UGOCXCATBP	Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, Carboplatin, Paclitaxel and Pembrolizumab	<i>Eligibility note added</i>	---	---
UGOCXCATP	Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Carboplatin, Paclitaxel and Pembrolizumab	<i>Eligibility note added</i>	---	---
UGOEAVDCAT	Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel	<i>Requirement for CAP approval removed; protocol code revised</i>	<i>Requirement for CAP approval removed; protocol code revised</i>	---
UGOEAVDPNC	Alternative Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	<i>Requirement for CAP approval removed; protocol code revised</i>	<i>Requirement for CAP approval removed; protocol code revised</i>	---
GU Genitourinary				
GUAVEV	Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	<i>Dose banding added; contact information updated</i>	<i>Dose banding added; height/BSA removed; tests and treatment clarified</i>	---
GUAVEVPEM	First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Enfortumab Vedotin and Pembrolizumab	<i>Dose banding added</i>	<i>Dose banding added</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUBAVE	Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab	<i>Dose banding added; contact physician updated; tests and units of measure clarified</i>	<i>Dose banding added; units of measure and tests clarified</i>	---
GUSUNI	Palliative Therapy for Renal Cell Carcinoma using Sunitinib	<i>Cautions, tests and contact information updated; eligibility clarified</i>	<i>Tests updated; treatment clarified</i>	<i>Spelling; clarifications</i>
LU Lung				
LUMMIPNI	Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	<i>Eligibility and contact physician updated</i>	---	---
LUMMIPN3	Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	<i>Eligibility and contact physician updated</i>	---	---
LUNANIVPC	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, Carboplatin and Paclitaxel	<i>Protocol code revised</i>	<i>Protocol code revised</i>	---
LUNANIVPP	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	<i>Protocol code revised</i>	<i>Protocol code revised</i>	---
LY Lymphoma				
LYAVDNIV	Treatment of Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Nivolumab	<i>Eligibility updated; imaging guidance added to treatment section</i>	---	---
LYPOLARCHP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Prednisone, Rituximab and Polatuzumab Vedotin	<i>Precautions updated</i>	<i>Treatment section simplified</i>	---
SM Skin and Melanoma				
SMMCCAIVE	Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma using Avelumab	<i>Dose banding added; tests and units of measure clarified</i>	<i>Dose banding added; units of measure and tests clarified</i>	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	druginfo@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Mário de Lemos, PharmD, MSc(Oncol)
Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
Alison Pow, BScPharm
Yuna Jang, RN